AIV Logo AIV Assistant

Loading...

 Logo Enovis Corporation Common Stock - ENOV Open Enovis Corporation Common Stock in new tab

30.69
EPS
-14.95
P/B
0.73
ROE
-0.28
Beta
1.80

30.6900

30.690

Daily: -4.06%
Key Metrics

Earnings date: Nov. 6, 2025

EPS: -14.95

Book Value: 45.11

Price to Book: 0.73

Debt/Equity: 56.75

% Insiders: 0.016%

Growth

Revenue Growth: 0.08%

Estimates

Forward P/E: 10.40

Forward EPS: 3.16

 Logo About Enovis Corporation Common Stock - (ENOV)

Country: United States

Sector: Industrials

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion